Hansa Biopharma is leveraging its proprietary enzyme technology platform to enable immunomodulatory
treatments for transplants, rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and
cancer.
The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable
kidney transplantation in highly sensitized patients and may be further developed for use in other organ and
tissue transplantation and acute autoimmune indications. The European Commission has conditionally approved
Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant
patients with a positive crossmatch against an available deceased donor.
Hansa’s research and development program is also advancing the Company’s enzyme technology to develop the
next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in
relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations
in other European countries and in the U.S.